$0.50
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Langhorne, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-12-22. The company is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The firm operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. The company also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.
Country

US

CEO

Mr. Adam Levy

IPO date

2021

Employees

19

ISIN

US65344E1073

Website

nexgel.com

Key stats

Open

$0.50

Volume

60.24K

Market cap

$6.03M

Prev. close

$0.51

Impl / hst vl

-

Open interest

$0.00

$0.50

Day’s Range

$0.50

$0.48

52W Range

$1.90

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
0.54
P/B
1.51
Current ratio
1.70
Debt / Equity
0.49
ROE
-70.35%
Gross margin
40.04%
Income growth
-4.43%
FCF growth
-312.86

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$2.04
The top 3 analysts forecasts that 12-month price may increase by 308.00%, with a low of $2.02 and a high of $2.10
$2.02
Low
$2.04
Avg
$2.10
High
Current price

Earnings

Q1 ‘26 revenue
$2.65M
Q1 ‘26 net income
-$927.00K
Revenue
Net income
Previous EPS
-$0.11
Estimate EPS
-$0.12
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply